Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - ixekizumab, quantity: 80 mg/ml - injection, solution - excipient ingredients: water for injections; citric acid; sodium citrate dihydrate; polysorbate 80; sodium chloride - plaque psoriasis,taltz is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,psoriatic arthritis,taltz is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately, or who are intolerant, to previous dmard therapy.,taltz may be used as monotherapy or in combination with a conventional dmard (e.g. methotrexate).,axial spondyloarthritis - ankylosing spondylitis (radiographic axial spondyloarthritis),taltz is indicated for the treatment of active ankylosing spondylitis in adult patients.,axial spondyloarthritis - non-radiographic axial spondyloarthritis,taltz is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or mri evidence, who have responded inadequately to, or are intolerant to, nonsteroidal anti-inflammatory drugs (nsaids).

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - fluoxetine hydrochloride, quantity: 22.36 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: iron oxide yellow; titanium dioxide; pregelatinised maize starch; gelatin; dimeticone 350; patent blue v; indigo carmine; butan-1-ol; shellac; iron oxide black - prozac is indicated for the treatment of: major depression. obsessive complusive disorder. premenstrual dysphoric disorder (pmdd) as defined by dmv-iv criteria. the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; metacresol; hydrochloric acid; glycerol - other conditions: refrigerate - do not freeze. indications: for the treatment of insulin dependent diabetic patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: water for injections; sodium hydroxide; protamine sulfate; phenol; dibasic sodium phosphate heptahydrate; glycerol; metacresol; hydrochloric acid; zinc oxide - for the treatment of insulin dependent diabetic patients.